Format

Send to

Choose Destination
Arch Neurol. 2002 Jul;59(7):1133-6.

Down syndrome and Alzheimer disease: response to donepezil.

Author information

1
Department of Pediatrics, University of California, Irvine Medical Center, 101 The City Dr S, Bldg 2, Third Floor, Orange, CA 92868-4482, USA. Itlott@uci.edu

Abstract

BACKGROUND:

Individuals with Down syndrome who develop Alzheimer disease may show an improvement in cognitive functioning after treatment with acetylcholinesterase inhibitors.

OBJECTIVE:

To determine whether individuals with Down syndrome and Alzheimer disease will show improvement after institution of donepezil treatment.

DESIGN:

A nonrandomized controlled trial using donepezil in a pilot study format.

SETTING:

Academic medical center.

PATIENTS:

Convenience sample of 6 treated patients with Down syndrome and 9 closely matched historical control subjects.

INTERVENTION:

Oral administration of donepezil for a 5-month period.

PRIMARY OUTCOME MEASURE:

The Down Syndrome Dementia Scale.

RESULTS:

Significant improvement in dementia scores for the treated group during a 3- to 5-month period (P =.03).

CONCLUSIONS:

Acetylcholinesterase inhibitors may be helpful in reversing the symptoms of dementia during early and middle stages of cognitive decline. These findings support the rationale for a more extensive study of the efficacy of acetylcholinesterase inhibitors in Down syndrome dementia.

PMID:
12117361
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center